Annual SG&A
$142.52 M
+$33.44 M+30.66%
31 December 2023
Summary:
Esperion Therapeutics annual selling, general & administrative expenses is currently $142.52 million, with the most recent change of +$33.44 million (+30.66%) on 31 December 2023. During the last 3 years, it has fallen by -$57.09 million (-28.60%). ESPR annual SG&A is now -28.60% below its all-time high of $199.62 million, reached on 31 December 2020.ESPR Selling, General & Administrative Expenses Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly SG&A
$39.98 M
-$4.21 M-9.53%
30 September 2024
Summary:
Esperion Therapeutics quarterly selling, general & administrative expenses is currently $39.98 million, with the most recent change of -$4.21 million (-9.53%) on 30 September 2024. Over the past year, it has increased by +$6.74 million (+20.26%). ESPR quarterly SG&A is now -35.06% below its all-time high of $61.55 million, reached on 31 December 2020.ESPR Quarterly SG&A Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM SG&A
-$6.17 B
-$86.77 M-1.43%
30 September 2024
Summary:
Esperion Therapeutics TTM selling, general & administrative expenses is currently -$6.17 billion, with the most recent change of -$86.77 million (-1.43%) on 30 September 2024. Over the past year, it has dropped by -$6.29 billion (-5187.06%). ESPR TTM SG&A is now -14593.14% below its all-time high of $219.13 million, reached on 31 March 2021.ESPR TTM SG&A Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
ESPR Selling, General & Administrative Expenses Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +30.7% | +20.3% | -5187.1% |
| 3 y3 years | -28.6% | +1.8% | -3062.2% |
| 5 y5 years | +330.6% | +116.5% | -10000.0% |
ESPR Selling, General & Administrative Expenses High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -28.6% | +30.7% | -12.0% | +65.6% | -63.1% | at low |
| 5 y | 5 years | -28.6% | +330.6% | -35.1% | +116.5% | -167.3% | at low |
| alltime | all time | -28.6% | +6360.7% | -35.1% | +7798.6% | <-9999.0% | at low |
Esperion Therapeutics Selling, General & Administrative Expenses History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | $39.98 M(-9.5%) | $171.57 M(+4.1%) |
| June 2024 | - | $44.19 M(+5.2%) | $164.84 M(+6.6%) |
| Mar 2024 | - | $41.99 M(-7.6%) | $154.61 M(+8.5%) |
| Dec 2023 | $142.52 M(+30.7%) | $45.42 M(+36.7%) | $142.52 M(+17.6%) |
| Sept 2023 | - | $33.24 M(-2.1%) | $121.24 M(+7.3%) |
| June 2023 | - | $33.96 M(+13.6%) | $112.95 M(+4.0%) |
| Mar 2023 | - | $29.90 M(+23.9%) | $108.60 M(-0.4%) |
| Dec 2022 | $109.08 M(-41.0%) | $24.14 M(-3.3%) | $109.08 M(-11.5%) |
| Sept 2022 | - | $24.95 M(-15.7%) | $123.28 M(-10.4%) |
| June 2022 | - | $29.61 M(-2.5%) | $137.59 M(-10.8%) |
| Mar 2022 | - | $30.38 M(-20.8%) | $154.30 M(-16.6%) |
| Dec 2021 | $184.99 M(-7.3%) | $38.34 M(-2.4%) | $184.99 M(-11.2%) |
| Sept 2021 | - | $39.27 M(-15.2%) | $208.20 M(-4.4%) |
| June 2021 | - | $46.32 M(-24.1%) | $217.76 M(-0.6%) |
| Mar 2021 | - | $61.06 M(-0.8%) | $219.13 M(+9.8%) |
| Dec 2020 | $199.62 M(+203.1%) | $61.55 M(+26.1%) | $199.62 M(+24.9%) |
| Sept 2020 | - | $48.83 M(+2.4%) | $159.77 M(+23.5%) |
| June 2020 | - | $47.68 M(+14.7%) | $129.41 M(+35.9%) |
| Mar 2020 | - | $41.55 M(+91.4%) | $95.22 M(+44.6%) |
| Dec 2019 | $65.85 M(+99.0%) | $21.71 M(+17.6%) | $65.85 M(+19.0%) |
| Sept 2019 | - | $18.47 M(+36.9%) | $55.32 M(+20.6%) |
| June 2019 | - | $13.49 M(+10.8%) | $45.86 M(+16.6%) |
| Mar 2019 | - | $12.18 M(+9.0%) | $39.33 M(+18.8%) |
| Dec 2018 | $33.10 M(+54.8%) | $11.18 M(+24.0%) | $33.10 M(+21.8%) |
| Sept 2018 | - | $9.01 M(+29.5%) | $27.18 M(+14.0%) |
| June 2018 | - | $6.96 M(+16.8%) | $23.85 M(+6.9%) |
| Mar 2018 | - | $5.95 M(+13.3%) | $22.30 M(+4.3%) |
| Dec 2017 | $21.38 M | $5.26 M(-7.5%) | $21.38 M(+4.2%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2017 | - | $5.68 M(+5.0%) | $20.53 M(+7.7%) |
| June 2017 | - | $5.41 M(+7.6%) | $19.06 M(+4.3%) |
| Mar 2017 | - | $5.03 M(+14.2%) | $18.28 M(-0.0%) |
| Dec 2016 | $18.28 M(-9.7%) | $4.40 M(+4.5%) | $18.28 M(-4.6%) |
| Sept 2016 | - | $4.21 M(-9.0%) | $19.16 M(-7.1%) |
| June 2016 | - | $4.63 M(-7.9%) | $20.61 M(-2.9%) |
| Mar 2016 | - | $5.03 M(-4.7%) | $21.23 M(+4.9%) |
| Dec 2015 | $20.24 M(+85.3%) | $5.28 M(-6.9%) | $20.24 M(+11.6%) |
| Sept 2015 | - | $5.67 M(+8.0%) | $18.14 M(+21.0%) |
| June 2015 | - | $5.25 M(+30.2%) | $14.99 M(+20.3%) |
| Mar 2015 | - | $4.04 M(+26.9%) | $12.47 M(+14.1%) |
| Dec 2014 | $10.92 M(+61.9%) | $3.18 M(+25.9%) | $10.92 M(+7.7%) |
| Sept 2014 | - | $2.53 M(-7.3%) | $10.14 M(+6.3%) |
| June 2014 | - | $2.73 M(+9.5%) | $9.54 M(+19.5%) |
| Mar 2014 | - | $2.49 M(+3.8%) | $7.98 M(+18.4%) |
| Dec 2013 | $6.75 M(+205.8%) | $2.40 M(+24.6%) | $6.75 M(+39.0%) |
| Sept 2013 | - | $1.92 M(+64.2%) | $4.85 M(+40.1%) |
| June 2013 | - | $1.17 M(-6.3%) | $3.46 M(+22.6%) |
| Mar 2013 | - | $1.25 M(+147.2%) | $2.82 M(+28.0%) |
| Dec 2012 | $2.21 M(-6.4%) | $506.10 K(-5.2%) | $2.21 M(+29.8%) |
| Sept 2012 | - | $533.80 K(+0.0%) | $1.70 M(+45.8%) |
| June 2012 | - | $533.70 K(-15.6%) | $1.17 M(+84.4%) |
| Mar 2012 | - | $632.40 K | $632.40 K |
| Dec 2011 | $2.36 M(-60.4%) | - | - |
| Dec 2002 | $5.96 M(+18.6%) | - | - |
| Dec 2001 | $5.02 M(+70.3%) | - | - |
| Dec 2000 | $2.95 M(+17.1%) | - | - |
| Dec 1999 | $2.52 M | - | - |
FAQ
- What is Esperion Therapeutics annual selling, general & administrative expenses?
- What is the all time high annual SG&A for Esperion Therapeutics?
- What is Esperion Therapeutics annual SG&A year-on-year change?
- What is Esperion Therapeutics quarterly selling, general & administrative expenses?
- What is the all time high quarterly SG&A for Esperion Therapeutics?
- What is Esperion Therapeutics quarterly SG&A year-on-year change?
- What is Esperion Therapeutics TTM selling, general & administrative expenses?
- What is the all time high TTM SG&A for Esperion Therapeutics?
- What is Esperion Therapeutics TTM SG&A year-on-year change?
What is Esperion Therapeutics annual selling, general & administrative expenses?
The current annual SG&A of ESPR is $142.52 M
What is the all time high annual SG&A for Esperion Therapeutics?
Esperion Therapeutics all-time high annual selling, general & administrative expenses is $199.62 M
What is Esperion Therapeutics annual SG&A year-on-year change?
Over the past year, ESPR annual selling, general & administrative expenses has changed by +$33.44 M (+30.66%)
What is Esperion Therapeutics quarterly selling, general & administrative expenses?
The current quarterly SG&A of ESPR is $39.98 M
What is the all time high quarterly SG&A for Esperion Therapeutics?
Esperion Therapeutics all-time high quarterly selling, general & administrative expenses is $61.55 M
What is Esperion Therapeutics quarterly SG&A year-on-year change?
Over the past year, ESPR quarterly selling, general & administrative expenses has changed by +$6.74 M (+20.26%)
What is Esperion Therapeutics TTM selling, general & administrative expenses?
The current TTM SG&A of ESPR is -$6.17 B
What is the all time high TTM SG&A for Esperion Therapeutics?
Esperion Therapeutics all-time high TTM selling, general & administrative expenses is $219.13 M
What is Esperion Therapeutics TTM SG&A year-on-year change?
Over the past year, ESPR TTM selling, general & administrative expenses has changed by -$6.29 B (-5187.06%)